Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

When investors are paying such high price tags for a stock, expectations are high, and any kind of miss can result in a steep ...

Eli Lilly (NYSE: LLY) began a roll in late 2020 that lasted almost four years. During that time, it became the world's ...

The American Association of University Women of Iowa is celebrating the anniversary of a law aimed to fight pay ...

this man has become, Carl, a nation-state within ... An array of pharmaceutical pills with the company's logo on the bottle. Eli Lilly and Company (NYSE:LLY) is one of the hottest healthcare stocks on ...

In a report released today, Terence Flynn from Morgan Stanley reiterated a Buy rating on Eli Lilly & Co (LLY – Research Report), with a ...

What is said in the jungle does not stay in the jungle. And so viewers of the jungle camp now know how Lilly Becker once fell ...

The anti-obesity drug Zepbound made by Eli Lilly & Co. could be one of the biggest cost drivers for ... [+] health insurers, employers and government health programs who cover it in 2025.

Eli Lilly can’t seem to recover from its GLP-1 stumble. Once again, the drugmaker reported sales of its blockbuster GLP-1 medicines Zepbound and Mounjaro that missed Wall Street estimates.

Eli Lilly shares fell after the drugmaker warned that sales of its hot diabetes and anti-obesity drugs are growing more slowly than expected. Lilly now expects fourth-quarter sales of $3.5 billion for ...

Eli Lilly is intervening in a lawsuit filed by a trade group representing compounding pharmacies, aiming to block the FDA's determination that the shortage of its GLP-1 medications, Mounjaro and ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE ... now which I think is a little absurd.. . . this man has become, Carl, a nation-state within.